Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Short Interest Update

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) was the recipient of a large decline in short interest in February. As of February 13th, there was short interest totaling 8,412,337 shares, a decline of 14.1% from the January 29th total of 9,793,959 shares. Currently, 4.3% of the company’s stock are short sold. Based on an average trading volume of 2,748,111 shares, the short-interest ratio is presently 3.1 days. Based on an average trading volume of 2,748,111 shares, the short-interest ratio is presently 3.1 days. Currently, 4.3% of the company’s stock are short sold.

Institutional Trading of Zimmer Biomet

A number of large investors have recently bought and sold shares of the business. DV Equities LLC purchased a new stake in shares of Zimmer Biomet in the fourth quarter valued at about $25,000. Key Financial Inc raised its stake in Zimmer Biomet by 164.6% during the 3rd quarter. Key Financial Inc now owns 262 shares of the medical equipment provider’s stock valued at $26,000 after acquiring an additional 163 shares during the last quarter. Cullen Frost Bankers Inc. raised its stake in Zimmer Biomet by 66.7% during the 3rd quarter. Cullen Frost Bankers Inc. now owns 290 shares of the medical equipment provider’s stock valued at $29,000 after acquiring an additional 116 shares during the last quarter. Cary Street Partners Investment Advisory LLC lifted its position in Zimmer Biomet by 83.7% during the 2nd quarter. Cary Street Partners Investment Advisory LLC now owns 327 shares of the medical equipment provider’s stock worth $30,000 after acquiring an additional 149 shares during the period. Finally, Monetary Solutions Ltd acquired a new position in shares of Zimmer Biomet in the fourth quarter valued at approximately $30,000. Institutional investors and hedge funds own 88.89% of the company’s stock.

Zimmer Biomet Price Performance

ZBH stock opened at $93.33 on Friday. The company has a market capitalization of $18.26 billion, a PE ratio of 26.36, a P/E/G ratio of 1.96 and a beta of 0.58. Zimmer Biomet has a 12-month low of $84.59 and a 12-month high of $114.44. The company has a current ratio of 1.98, a quick ratio of 1.10 and a debt-to-equity ratio of 0.55. The business’s fifty day moving average price is $92.06 and its 200 day moving average price is $95.79.

Zimmer Biomet (NYSE:ZBH) last released its earnings results on Tuesday, February 10th. The medical equipment provider reported $2.42 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.38 by $0.04. Zimmer Biomet had a return on equity of 12.93% and a net margin of 8.56%.The firm had revenue of $2.24 billion during the quarter, compared to analyst estimates of $2.22 billion. During the same period last year, the business posted $2.31 earnings per share. Zimmer Biomet’s revenue was up 10.9% compared to the same quarter last year. Zimmer Biomet has set its FY 2026 guidance at 8.300-8.450 EPS. On average, sell-side analysts anticipate that Zimmer Biomet will post 8.22 EPS for the current year.

Zimmer Biomet Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, April 30th. Shareholders of record on Tuesday, March 31st will be paid a $0.24 dividend. The ex-dividend date is Tuesday, March 31st. This represents a $0.96 dividend on an annualized basis and a yield of 1.0%. Zimmer Biomet’s payout ratio is currently 27.12%.

Analyst Ratings Changes

Several equities research analysts have weighed in on ZBH shares. JPMorgan Chase & Co. reissued a “neutral” rating and issued a $100.00 price target (down from $115.00) on shares of Zimmer Biomet in a report on Thursday, November 6th. Robert W. Baird restated a “neutral” rating and issued a $100.00 price objective (down from $117.00) on shares of Zimmer Biomet in a research report on Tuesday, December 16th. Canaccord Genuity Group dropped their price target on shares of Zimmer Biomet from $101.00 to $93.00 and set a “hold” rating on the stock in a research report on Monday, November 10th. Royal Bank Of Canada cut their price objective on Zimmer Biomet from $111.00 to $101.00 and set an “outperform” rating for the company in a research report on Thursday, November 6th. Finally, Evercore upgraded shares of Zimmer Biomet from an “in-line” rating to an “outperform” rating and upped their price target for the stock from $94.00 to $120.00 in a research report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, ten have issued a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus target price of $106.20.

Zimmer Biomet Company Profile

Zimmer Biomet (NYSE: ZBH) is a global medical device company focused on musculoskeletal healthcare. Headquartered in Warsaw, Indiana, the company designs, manufactures and markets a broad portfolio of products used to treat joint disorders, bone disorders and related conditions. Its customer base includes orthopaedic and dental surgeons, hospitals, ambulatory surgery centers and other healthcare providers that rely on implants, instruments and related services for reconstructive and restorative procedures.

The company’s product offerings span joint replacement systems for hips, knees and shoulders; trauma and extremities implants; spine and thoracic solutions; dental and craniomaxillofacial implants and prosthetics; and sports medicine devices.